Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.

Regeneron Pharmaceuticals (REGN) announced its newly approved gene therapy, Otarmeni, will be offered for free in the U.S. while pricing in other countries is still undecided. CEO Leonard Schleifer indicated they are determining a fair price internationally. In clinical trials, 80% of participants saw hearing improvements, with estimates suggesting around 50 babies born annually in the U.S. with the condition. Analysts from Piper Sandler project peak sales of $130 million, emphasizing the limited financial impact due to the condition's rarity.